Eli Lilly Stock Surges on Obesity-Drug Boom – Is $1,000 Next?
In early October 2025, Eli Lilly stock leapt upward. After closing around $726 on Sept. 29 and ~$763 on Sept. 30 nasdaq.com, it spiked to about $832 intraday on Oct. 1. Trading volumes were well above average on that run. Financial media noted a flurry of bullish option trades and news-driven optimism: a major study found that GLP-1 weight-loss drugs may significantly reduce Alzheimer’s risk fiercepharma.com, feeding excitement about Lilly’s broad pipeline. Tip-rank and investing sites attributed the rally to strong earnings, insider buying, and renewed interest in Lilly’s obesity/Alzheimer’s franchise tipranks.com fiercepharma.com. Overall, LLY’s late-Sept gains outpaced the broader market, reflecting investor confidence in Lilly’s growth drivers.
